Pfiz­er's Al­bert Bourla turns to an ac­com­plished deal­mak­er, strat­e­gy ex­pert for its next CFO

David Den­ton, who was dis­placed as CFO of CVS af­ter help­ing en­gi­neer the $69 bil­lion merg­er of his com­pa­ny with Aet­na, is jump­ing in­to the top num­bers job at Pfiz­er.

Most re­cent­ly work­ing as CFO of home im­prove­ment gi­ant Lowe’s, Den­ton is mov­ing in­to the C-suite as Pfiz­er is wide­ly ex­pect­ed to be­gin us­ing its multi­bil­lion-dol­lar Covid-19 wind­fall for a slate of new buy­outs and drug deals.

Den­ton is re­plac­ing Frank D’Ame­lio, who is re­tir­ing from Pfiz­er af­ter a 15-year stint. Den­ton had ex­it­ed CVS in the wake of the Aet­na merg­er, grab­bing 2 years’ salary on his way out to a new post­ing at Lowe’s. He’s been giv­en top marks by his em­ploy­ers for strate­gic think­ing, land­ing in­side the in­ner cir­cle of Bourla’s at a key mo­ment for Pfiz­er and bio­phar­ma in gen­er­al.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER